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1. Introduction
The strength and breadth of nuclear cardiology lie in its great potential for future creative
growth. This growth involves the development of new biologically derived radiopharmaceut‐
icals, avdanced imaging techologies, and a broad/based set of research and clinical aplications
involving diagnosis, functional categorization, prognosis, evaluation of therapeutic interven‐
tions, and the ability to deal with many of the major investigative issues in contemporary
cardiology such as myocardial hibernation, stunning, and viability. The past decade has been
caracteriyed by major advances in nuclear cardiology that have greatly enhanced the clinical
utility of the various radionuclide techniques used for the assessment of regional myocardial
perfusion and regional and global left ventricular function under resting and stress condotions.
Despite the emergence of alternative noninvasive techniques for the diagnosis of coronary
aretry disease (CAD) and the assessment of prognosis of viability, such as ergo- stress tests,
stress echocardiography, the use and application of nuclear cardiology techniques have
continued to increase. The establishment of the American Society of Nuclear Cardiology
(ASNC) and its educational programs has led to a greater diffusion on nuclear cardiology
technology in the community hospital setings and has promoted the emergence and dissem‐
ination of imaging and procedural guidelines for nuclear cardiology methods. The establish‐
ment of the Journal of Nuclear Cardiology, the official journal of ASNC, allowed a greater
number of manuscript to be published in the field [1, 2, 3]
In the few past decade, significant advances have been made in the ability to image the heart
with radionuclide tracers under stress and resting conditions in patientse with suspected or
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known coronary aretry disease (CAD) for the detection of ischemia, determination of prog‐
nosis, assessment of myocardial viability, preoperative risk assessment for patients undergo‐
ing noncardiac surgery, mand evaluation of the efficacy of revasculariyation in patients
undergoing coronary artery bypass surgery or an interventional procedure [1, 2, 3].
For many years, planar imaging and SPECT with 201Tl (201 Talium) constituted the only
scintigrafic techniques available for detecting CAD and assessing prognosis in patients
undergoing stress perfusion imaging. The major limitation of 201Tl scintigraphy is the high
false/positive rate observed in many laboratories, wich is attributed predominantly to image
attenuation aretfact and variants of normal that are interpreted as defects consequent to a
significant coronary artery stenoses. Although quantification of 201Tl images improves
specificity, the false/positive rate remains problematic, particulary in the women and in obese
patients. Breast attenuation artifact in women are sometimes difficult to distiguish from
perfusion abnormalities secondary to inducible ischemia or myocardial scar.
In recent years, new 99mTc (technetium) labeled perfusion agents have been introduced into
clinical practice to enhance the specificity of Single Photon Emission Cumputed Tomography
(SPECT) and to provide additional information regarding and global left ventricular systolic
function via ECG gating of images [3, 4, 8]. It was immadiately apparent that the quality of
images obtained with these 99mTc-labeled radionuclides was superior to that images obtained
with 201Tl because of the more favorable psysical characteristic of 99mTc imaging with gamma
camera. Perhaps most importantly, 99mTc imaging allows easy gated acqusition, permiting
simulateous evaluation of regional systolic thickening, global left ventricular function (LVEF),
and myocardial perfusion. One the most significant avdances in myocardial perfusion imaging
in the past decade is the development of quantitative SPECT perfusion imaging. Radionuclide
imaging is an intrinsically digital technique that is ideally suited for quantification. A number
of validated software packages are commercially available for quantification of SPECT
myocardial perfusion and function (Auto Quant; Emory Toolbox; 4D/MSPECT; and Wackers
Liu CQ), and are carried by the major vendors of nuclear medicine imaging equipment. The
basic principles of SPECTR quantification are similar for each of these software packages. Each
commercially available package also includes software for computation of LVEF and left
ventricular volumes from ECG-gated SPECT images [7, 9, 10, 11].
2. Indications for nuclear cardiology procedures
2.1. Suspected coronary artery disease
CAD is still the single greatest cause of death of men and women in the world, despite a
declining total death rate. Using USA data over 459.000 deaths were due to CAD -1 of every
deaths. There are aproximatelly 2.2 million hospital discharges with CAD as the diagnosis
annually.
The reduction of the morbidity and mortality due to CAD is thus primary importance to
physicians and patients. Stress myocardial perfusion imaging (MPI) has emerged as an
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important noninvasive means of evaluating patients with suspected CAD, with over than 10
millions studies performed in USA annually [1, 2, 16, 17, 18].
Risk factor assessment
The first step in evaluating patients for CAD involves the assessment of the presence of
traditional risk factors. Modifiable risks include hypercholesterolemia, hypertension, diabetes
mellitus, obesity, tobacco use, and physical inactivity. Nonmodifiable risk factor includes a
family history of CAD in first-degree relatives under the age of 60, advanced age, and gender?
Once risk factors associated with CAD are evaluated, a patient's risk for having CAD should
be assessed. This is often performed by taking symptoms such as a chest pain, age, and gender
into account. Symptoms suggestive of CAD, in addition to other risk factors, drive decisions
for further testing [2, 12, 17, 18].
A cornerstone of the diagnosis of CAD has been exercise tolerance testing (ETT). The ETT is
the safe and easily performed, usually in an office setting. But generally, ETT electrocardiog‐
raphy (ECG) has a sensitivity of 50 to 70%, and a specificity of 60 to 80%.
Thus, the major limitation of the ETT is its diagnostic accuracy for the detection of significant
CAD. In patients able to exercise, the diagnostic accuracy of stress myocardial perfusion
imaging (MPI) is significantly higher than the ETT alone and provides greater risk stratification
for predicting the future cardiac events.
(Nuclear cardiology –practical applications)
ETT exercise treadmill test
DIP-ECHO dipyridamole echocardiography
DOB-ECHO dobutamine echocardiography
DIP- MIBI dipyridamole myocardial perfusion imaging with Tc-99m MIBI
DOB-MIBI dobutamine myocardial perfusion imaging with Tc-99m MIBI
Figure 1. Diagnostic accuracy of various tests of CAD
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Because of limitation to performed exercise test (patients with medical illness, debilitation,
musculoskeletal problems, and the older who can’t reach a predicted maximum heart rate)
MPI with pharmacologic stress using vasodilators (dipyridamole, and adenosine) or dobuta‐
mine can be implemented in such patients. In this moment, it has been estimated that 48% to
50% of all stress MPI is performed with pharmacologic agent. Briefly, dipyridamole and
adenosine are potent coronary vasodilators that markedly increase coronary blood flow. This
increased flow is less pronounced in arteries that are stenotic (flow restricted) due to athero‐
sclerosis. This causes heterogeneous myocardial perfusion, which can be observed using that
follows coronary blood flow as an alternative to vasodilator stress. Dobutamine works by
increasing myocardial oxygen demand (through increased heart rate, systolic blood pressure,
and myocardial contractility) [5, 6, 7, 8, 9]. As in exercise MPI scintigraphic images obtained
at rest compared to those obtained during peak pharmacologic stress to distinguish myocardial
ischemia from scar tissue (infarct area).
The diagnostic accuracy of Tc-99m imaging with pharmacologic stress test for angiographi‐
cally significant CAD has been evaluated in numerous study.
(Nuclear cardiology –practical applications)
Figure 2. Diagnostic accuracy of stress myocardial perfusion imaging.
2.2. Evaluating and determination CULPRIT lesion, in indication for interventional
cardiology
One of the most powerfull uses of MPI is the evaluation of the risk for future events in patients
with suspected or known CAD. Over the years, MPI has evolved as an essential tool in the
evaluation and assessment of patient prior to coronary revascularization. It has a dual role.
Prior to coronary angiography, MPI is extremly useful in documeting ischemia and determin‐
ing the functional impact of single or multiple lesions indentified subsequently. After coronary
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anatomy is known, and despite some limitations in the setting of multivessel disease, MPI
remains the test of choise for indentifying the lesion responsible for the ischemic symptoms,
or so colled culprit lesion. That is extremly useful for futher management decisions with respect
to percutaneous interventions. In compare, the absence of reversible ischemia in patients with
known CAD is an excellent prognostic marker and predicts a low annual event rate.
The current definition of culprit lesion that is zone of ischemia under the coronary stenoses is
not quite wright, because that is not definy two pathophysiologic aspects of ischemia; severity
and extent. The primary objective of those study was to determinate and localizes culprit lesion
by newly introduce parameters SRS (summary reversible score) and ISRS (index of summary
reversible score), under the angiographically detected coronary narrowing ≥75% for the least
one coronary artery [2, 6, 9, 11, 15].
In the past two decades, a great body of literature has established the use of nuclear imaging
for risk stratification in patients with known or suspected coronary artery disease (CAD).
Risk  stratification  is  of  crucial  importance  for  the  practice  of  contemporary  medicine.
Extending the paradigm of noninvasive cardiac testing beyond the detection of disease is
especially important, may risk assessment permits patients who are identified as being at
a high risk for subsequent cardiac events should receive aggressive management,  possi‐
bly including cardiac catheterization for potential  revascularization procedures that  may
improve their outcome. CAD is disease with a wide spectrum of severity and extent with
outcome, such as nonfatal myocardial infarction (MI) or cardiac death being related to the
severity of disease. Clinical trials have shown that patients with severe CAD as left main
coronary artery disease, especially those with left ventricular dysfunction, can benefit from
coronary artery bypass graft surgery (CABG) with significant reduction in their mortality
rate. Whereas patients with single-vessel or with two-vessel disease (without proximal left
anterior  descending  artery  involvement)  would  have  improved  symptoms  of  angina
following CABG and percutaneous transluminal coronary angioplasty with or without stent
implantation, without any effect on their mortality rate.
Coronary angiography, considered the “gold standard” for the diagnosis of CAD, often does
not provide information about the physiologic significance of atherosclerotic lesions, espe‐
cially in borderline lesions. More importantly, it does not provide a clear marker of risk of
adverse events, especially in patients with moderate disease severity. Andreas Gruentzig said;
“When coronary angiography founded coronary artery disease, I would like to have diagnostic procedure
who will give me functional significance that lesion.” [2, 10, 12, 18].
The  presence  of  normal  scintigraphic  MPI  study  at  a  high  level  of  stress  ( ≥  85  %  of
maximum  predicted  heart  rate)  or  proper  pharmacologic  stress  carries  a  very  benign
prognosis, with mortality rate less than 0.5% per year. This finding has been reproduced
in many studies. Iskander and Iskandiran, pooling the results of SPECT imaging from more
than 12000 patients in 14 studies, demonstrated that the events rate (death/MI) for patients
with normal MPI finding is 0.6%, whereas abnormal study carries 7.4% per year event rate,
a 12-fold increase [2, 3, 14, 18]..
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The current definition of culprit lesion; that is zone of ischemia under the coronary stenoses
(what degree? That is not definition. Some autors ofer degree of stenoses ≤ 70 %, some ≤ 75%,
even < 80-85% ) is not quite wright, because that is not definy two pathophysiologic aspects of
ischemia; severity and extent. Iskander and Iskadrian have also shown that defects reversibility
is an important predictor of type of cardiac events, whereas reversible perfusion defects are
associated with nonfatal MI. This is very important finding, since a reversible defect on MPI
imaging is the only available diagnostic tool that can independently predict the risk of nonfatal
MI. Therefore, stress perfusion studies should be reported documenting defect severity (mild,
moderate, severe), size (small, moderate, large) and reversibility to provide essential risk
stratification.[2, 3, 16].
The size and severity of the perfusion abnormality provide powerful prognostic information
and has been shown to directly relate to outcome. MPI perfusion imaging and determination
of culprit lesion is more predicitble of cardiac events than coronary angiography. As MPI
imaging may identify those patients at high risk for subsequent cardiac events, perfusion
imaging may be used to help guide further testing and revascularization procedures, and this
obviously has important cost-effectiveness ramifications.
The primary objective of this study was to determinate and localizes culprit lesion by newly
introduce parameters SRS (summary reversible score) and ISRS (index of summary reversible
score), under the angiographically detected coronary narrowing ≥75% for the least one coronary
artery [2].
The rapid rates of technical advances and improved operator expertise have enabled this
technique to gain more widespread application. Despite the large number of PTCA-s per‐
formed yearly, preprocedure documentation of myocardial ischemia is uncommon, occurring
in only 29% of patients.
Myocardial perfusion imaging provides information on the extent and location of myocardial
ischemia. The assessment of jeopardized myocardium may be performed and provides a
measure of the relative value of PTCA in terms of the amount of jeopardized myocardium.
The location of the stenosis may dictate the area at risk: extent and severity of perfusion defects
were significantly smaller in patients with proximal compared with distal coronary artery
occlusions.
Before revascularization is performed, myocardial perfusion imaging may assist in manage‐
ment decisions by demonstrating the presence of myocardial ischemia, viability and delineat‐
ing the severity and extent of coronary artery disease. The significance of equivocal lesions
may be determined and culprit vessel may be successfully defined by SPECT imaging before
angioplasty [2, 3, 10, 18].
The coronary angiography provides information on the anatomical state of the coronary tree
and, specifically, on the large epicardial arteries, while perfusion SPECT facilitates the
evaluation of the grade of ischemia that a particular stenosis produces. MPI SPECT is of
considerable use in the procedural indications of partial revascularization in patients with
chronic coronary artery disease (CAD). In these cases the purpose is to detect the coronary
stenosis that provokes the ischemia and is termed the "culprit lesion".
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The aim of the study Baskot at all. [2] was to determine and localize culprit lesion by MPI in
cases of angiographically detected coronary narrowing ≥ 75% of at least one coronary artery.
In the study four hundred and thirty-seven [437] patients were studied. In all of them angio‐
graphically detected significant coronary narrowing (≥ 75% luminal stenosis) before PCI. All
the patients were submitted to MPI 99mTc-MIBI, with pharmacologic dipyridamole stress
protocol with concomitant low level bicycle exercise 50 W (DipyEX). We measured relative
uptake 99mTc-MIBI for each myocardial segment using short-axis tomogram study. A 5-point
scoring system was used to assess the difference between uptake degree in stress and rest
studies for the same segment, and we created two indices: Sum reversible score (SRS), Index
of sum reversibility score (ISRS). In the results a total 1311 vascular territories (7429 segments)
were analyzed before elective percutaneous coronary intervention (ePCI). Overall sensitivity,
specificity and accuracy using SRS were 89.7%, 86, 7%, and 88, 2%, with a positive predictive
value of 92, 7%. Overall sensitivity, specificity and accuracy using ISRS were 92.8%, 89.1%, and
92.3%, and the positive predictive value was 93.7%. Conclusion this work that is DipyEX MPI
with two indices created SRS and ISRS significantly improves sensitivity, specificity and
accuracy in the determination and localization of culprit lesion in patients undergoing elective
PCI. In this work author defined culprit lesion using two physiological aspects; severity of
ischemia and extension zone of ischemia. With quantification of these two parameters of
culprit lesion, the author determined patients who underwent ePCI with stent implantation,
and who had the best therapy effects with PCI therapy.
Case 1.
Figure showed culprit lesion in the inferolateral segments in the AdenoEx (up line slices) MPI study
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 Nearly after elective PCI intervention we performed MPI with normal finding of perfusion
Case 2.
• Patient male 61 year old. St post IM with revascularization 1996 triple ACB (LIMA – LAD;
venous graft on the D1 and
• In April 2010 performed SPECT MPI, finding sugested invasive intervention.
• Coronarography finding ;LM 90%, LAD occluded, LIMA graft wide open. Venous graft on
the D1 occluded.
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• ACx stenoses 90%, OM with tubular stenosis 50 -70%
• RCA dominant, occluded ostial, venous graft occluded okludiran.
• Performed PCI with stent implantation (Tsunami gold 3.5 x 15) on LM and ACX
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 In the same act PCI with stent implantation
 
Final effect PCI
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Control MPI after four month after PCI
We finding zone of reversible ischemia in the same area, suggest restenosis
Control Coronarography - fidning in stent stenonis
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 Re PCI with stent implantation
Final effect
Conversely, patients with high-risk scans may benefit from an early invasive strategy with a
view toward revascularization depending on coronary anatomical finding. A substantial
number of patients undergoing SPECT perfusion imaging will have mild ischemia without a
multi-vessel disease scan pattern. If patients with mild ischemia have good exercise tolerance,
they should be considered as candidates for intense medical therapy with follow-up exercise
SPECT imaging possibly at 1 year. Unpublished data from the Clinical Outcomes Utilizing
Revascularization and Aggressive Drug Evaluations (COURAGE) trial seem to indicate that
many ischemic defects may markedly improve with aggressive lowering of abnormal lipids
an the other pharmacological interventions. Hachamovitch and colleagues reported patients
with the mildly abnormal scan had a 0.8% annual cardiac death rate compared with 0.9% for
those who underwent revascularization. The death rate in medically treated patients who had
moderately abnormal scans was 2.3% versus 1.1% for such patients undergoing revasculari‐
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zation. Finally, patients with a severely abnormal scan treated medically had an annual cardiac
death rate of 4.6% versus 1.3% for such patients who were revascularized. In the second study,
these investigators showed that medically treated patients who had greater than 20% of the
total myocardium rendered ischemic had higher annual cardiac death rate (6.7%) compared
with 2.0% for patients with this degree of extensive ischemia who underwent revasculariza‐
tion. For patients with 10% or less of the total myocardium rendered ischemic, there was no
difference in outcome between medical therapy and revascularization.
Exercise myocardial perfusion imaging is a valuable adjunct for separating high to low risk
patients who present symptoms consistent with stable CAD, or in patients who have known
disease and in whom further prognostication is warranted. Multiple high-risk nuclear imaging
variables can be identified, and the greater the extent of exercise/induced ischemia, the greater
the risk of cardiac events. Adjunctive variables, such as transient ischemic cavity dilatation
and functional assessment with evaluation of regional wall thickening or wall motion and left
ventricular ejection fraction greatly assist in the risk stratification process [1, 3, 16, 18].
Nuclear cardiology is uniquely placed to address all the major determinants of prognosis in
CAD can be assessed by measurements of stress-induced perfusion or function. These
measurements include the amount of infarcted myocardium, the amount of jeopardized
myocardium (supplied by vessels with hemodynamically significant stenosis), and the degree
of jeopardy (tightness of the individual coronary stenosis). Recent evidence in large patient
cohorts has revealed that factor estimating the extent of left ventricular dysfunction (left
ventricular ejection fraction, extent of infarcted myocardium, transient ischemic dilatation of
the left ventricle and increasing lung uptake) are excellent predictors of cardiac mortality.
However, measurements of inducible ischemia are the best predictors of the development of
acute coronary syndromes. Several reports have shown that nuclear testing yields incremental
prognostic value over clinical information with respect to cardiac death, or the combination
of cardiac death and nonfatal myocardial infarction as isolated endpoints. Now it is possible
to tailor therapeutic decision making for an individual patient based upon combination of
clinical factors and nuclear scan results. Patients with severe perfusion abnormalities on their
stress image may have a five- to ten-fold higher likelihood of cardiac death versus patient with
a normal myocardial perfusion SPECT. If the defects perfusion determined as a culprit lesion,
invasive therapy (PCI) is an optimized outcome for that patient [2, 12, 13, 15].
The explosion of PTCA and stent placement in patients with single or multi-vessel disease has
created a necessity for early detection of restenosis. A number of clinical studies have docu‐
mented the usefulness of stress MPI for identifying restenosis in patients after PCI. One point
of controversy is the optimal time to performing SPECT imaging after coronary intervention.
Although current consensus in to obtain an exercise MPI study 4 to 6 weeks post intervention,
whenever indicated, the proper timing for use of MPI remains to be determined. Based on
existing knowledge about the timing interval of subacute thrombosis (< 4 weeks) and in-stent
restenosis (3-6 month), we purpose the algorithm as a guide for the management of patients
with known CAD after PCI [2, 15, 16, 18].
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No symptoms post PCI Typical Symptoms post PCI Atypical 
Stress MPI 4-6 weeks
less than 6 month more than 6 month
stress MPI
Coronary angiography MPI to guide treatment
PTCA- Stent (PCI)
Figure 3. Recommendation for the diagnostic treatment after PCI.
Asymptomatic patients may be considered for stress MPI 4 to 6 weeks post intervention in
order to assess the functional results of PCI and established a new baseline. Subsets of patients
that benefit from this approach include those at high risk post PCI (patients with decreased
LV function, proximal left anterior descending artery disease, previous sudden death, diabetes
mellitus, hazardous occupations, and suboptimal PCI results). Stress MPI is also recommended
in patients who develop atypical symptoms after PCI and there is necessity to assess whether
these symptoms represent ischemia. Patient with symptoms typical of ischemia < 6 months
post intervention should proceed with coronary angiography as a first step, unless contrain‐
dicated. If angina occurs later (> 6 months post PCI), stress/pharmacologic MPI can be used to
assess degree and area of ischemia, since progression of native coronary disease rather than
in-stent restenosis is more likely.
Incremental prognostic value of MPI; Because nuclear test are expensive the cost-effective‐
ness of these tests should demonstrate incremental prognostic information that cannot be
derived from less expensive modalities such as clinical patient history and risks factors,
standard ECG, and exercise ECG.
The combination clinical and exercise MPI variables provided greater prognostic information
than the combination of clinical and angiographic data. Iskandrian et al showed that in
medically treated patients with CAD, exercise SPECT imaging provided independent and
incremental prognostic information even when catheterization data are available. The extent
of perfusion abnormality was the single best predictor of prognosis. MPI added incremental
prognostic information and risk-stratified patient even after clinical and exercise information
were known. The incremental prognostic information about prognosis and need for coronary
angiography provided by MPI has additionally been demonstrated for specific patients
subsets: women, patient following coronary angioplasty or CABG, after MI, and with unstable
angina. Hachamovitch et al demonstrated the use of MPI to yield incremental prognostic
information toward the identification of cardiac death. Patient with a mildly abnormal scan
after exercise stress are at low risk for cardiac death, but intermediate risk for nonfatal MI. A
noninvasive strategy of optimizing medical therapy in this patient subgroup may result in
significant cost saving when compared with invasive management strategy [1, 2, 3, 12, 18].
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The prognostic efficacy of MPI is well established. Subsequent data have demonstrated in
various patient subsets that nuclear tests add significant and incremental predictive value to
less expensive clinical and exercise testing data. Angiographic data obtained from more
expensive cardiac catheterization procedures add little or no significant incremental prognos‐
tic value when added to the results of MPI.
The introduction of new drugs and interventional devices to treat CAD, coupled with the
arrival of manage care, has led to era of cost-containment within the practice of cardiology.
Stress MPI is increasingly seen as a gatekeeper for more costly diagnosis and interventional
procedures. Steingart et al evaluated 378 patients with a full range of pretest probabilities for
CAD, and demonstrated that the results of MPI significantly reduced referring physicians’
likelihood of recommending cardiac catheterization, on average by 49%.
Under managed care health systems that operate under cost-containment and capitation,
MPI will  continue to impact significantly on the decision to perform cardiac catheteriza‐
tion and to refer patients for coronary revascurization. Recommendations for invasive and
interventional  procedures  are  often  coupled  with  an  appropriate  understanding  of  the
prognostic  value  of  MPI.  Patients  with  the  normal  stress  radionuclide  study  do  not
generally require referral for additional procedures, even when the likelihood of underly‐
ing CAD is high, as based on clinical and stress ECG data. The need for cardiac catheter‐
ization and coronary revascularization rates should be based on the degree of abnormality
as  detected  by  MPI.  Thus,  there  is  an  increasing  role  of  MPI  to  play  an  important
gatekeeper  function  in  the  current  era  of  managed  care  and  emphasis  on  cost-contain‐
ment [2, 3, 8, 12, 18].
Stress MPI has became a central guide in decision making with regard to CAD patients. Stress
MPI is commonly used either before consideration of coronary revascularization or after its
performance, to optimize decision making for CAD patients. Stress MPI is also used after
myocardial revascularization procedures, to evaluate therapeutic efficacy; following the
stabilization of acute ischemic syndromes; to determine subsequent risk; and before the
performance of elective non-cardiac surgery, to identify the high-risk subsets of CAD patients
who will require coronary revascularization prior to elective surgery.
After all, MPI has became an important instrument in defining cardiac risk and in identifying
patients who are most likely to benefit from additional invasive diagnostic testing and
potential coronary revascularization. MPI demonstrated significant incremental prognostic
3. Heart failure — New approach of therapy and diagnostic evaluation of
therapy effect1
Heart failure (HF) is becoming the main clinical challenge in cardiology in the twenty - first
century and is associated with high morbidity and mortality. Heart failure is the third most
1 Zivkovic Miodrag, Baskot Branislav
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prevalent cardiovascular disease in the United States. An estimated 5 million people in the
USA have heart failure, and the prevalence of the condition increase to 10 million by 2040,
according to prediction. The prevalence of heart failure increase with age from less than 1% in
the 20 – 30-year-old age group to over 20% in people age 80 years and older. The diagnostic
and therapeutic costs involved are estimated to have exceeded $34 billion in only one year.
Despite advances in therapies, the long-term prognosis from patients with heart failure remain
poor; 80% of men and 70% of women greater than 65 years of age with heart failure die within
8 years [1, 2, 19, 20, 21].
3.1. What we need for good and quality therapy
The underllying etiology of HF needs to be determined; most patients have CAD (approxi‐
mately 70% - 80%). Nuclear imaging can help in the differentiation between patients with
ischemic and non-ischemic HF. In patients with ischemic cardiomiopathy, the precise coronary
anatomy is also needed to determinate if revascularization needs to be considered. At present,
invasive angiography is performed to obtain the coronary anatomy, but multi-slice CT (MSCT)
may also provide this information. The presence of ischemia and viability needs to be deter‐
mined to decide further if revascularization is indicated.
Nuclear imaging is considered the first choice technique for assessment of ischemia and
viability; booth single-photon emission CT (SPECT), and positron emission tomography (PET)
can provide this information.
Nuclear imaging can provide some indirect evidence in the differentiation between ischemic
and non-ischemic HF. With stress,-rest SPECT study, reversible defects indicate ischemia
and  fixed  defects  of  perfusion  indicates  scar  tissue;  booth  this  findings  are  markers  of
coronary artery disease. Moreover, lot of studies with nuclear perfusion imaging demon‐
strated that patients with ischemic HF had extensive and diffuse perfusion defects, whereas
tracer uptake (myocardial perfusion) was mostly homogeneous (ischemic) in patients with
non-ischemic HF.
Similarly,  PET studies  also  demonstrated that  patients  with  non-ischemic  HF had more
homogeneous  tracer  uptake,  whereas  patients  with  ischemic  HF  had  areas  of  severely
reduced uptake (reflecting scar formation). Accordingly, nuclear imaging can help in the
differentiation between ischemic and non-ischemic cardiomyopathy, but for the diagnosis
of  underlying  coronary  artery  disease,  visualization  of  the  coronary  artery  is  needed.
Invasive angiography is the technique of choice, but recently MSCT has been introduced
for noninvasive angiography. With 64-slice MSCT and dual-source slice MSCT, we obtained
more consistent image quality with improve visualization of the coronary artery tree. In
the  presence  of  a  flow-limiting  stenosis,  resting  myocardial  is  preserved,  but  once  an
increased  myocardial  oxygen  demand  occurs,  a  perfusion  demand-supply  mismatch
follows, resulting in myocardial ischemia. Then, a sequence of events is initiated, which is
referred  to  as  the  “ischemic  cascade”.  Perfusion  abnormalities  occur  at  an  early  stage,
whereas diastolic  and systolic  left  ventricular dysfunction occur later.  Accordingly,  such
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techniques  as  nuclear  imaging  that  defect  perfusion  abnormalities  should  have  a  high
sensitivity for detection of ischemia, because these abnormalities occur early in the cascade
[19, 20, 21].
In the heart failure patients, the combination between the coronary anatomy and the presence
of ischemia in the territories of the stenotic vessels determines the need for revascularization.
In the absence of ischemia, the presence of viability needs to evaluation.
Another nuclear study performed in the evaluating of therapy effects in HF, is radionu‐
clide angiography (RNV). That is the most reproducible, accurate, and simple method for
noninvasively assessing left ventricular ejection fraction (LVEF). RNV are now most often
used for serial assessment of LVEF in patients who undergo chemotherapy, assessment of
global  regional  wall  motion in patients with recent or old myocardial  infarction,  and in
patients with congestive heart failure. In the patients with heart failure, evaluation of left
ventricular systolic function is essential to plan management and determine prognosis. At
the present time most RNV are acquired by multiple – view planar image technique. In
this moment SPECT RNV is not routinely performed in most nuclear cardiology laborato‐
ries. The greatest attraction of SPECT RNV is the ability to evaluate cardiac chambers and
regional wall motion without overlap of other structures. LVEF may be calculated based
on count changes from either a conventional planar image (best septal) or from SPECT RNV.
In the pilot study Zivkovic, Baskot at all. We introduced new therapy, hyperbaric oxygenation
(HBO) and erythropoietin (EPO) in the treatment of heart failure. The aim of this study is to
show positive therapeutic effects of synergistic applications of HBO as a strong generator of
regenerator activities in human tissues, and recombinant EPO as a general growth factor, in
the treatment HF ischemic and non-ischemic origin [19, 20, 21].
HBO  is  medical  procedure  of  breathing  the  100%  oxygen  under  pressures  higher  than
atmospheric pressure is and it carries out into hyperbaric chambers. Contemporary, HBO
changes  the  rheological  blood  characteristic,  recovers  the  function  of  blood  vessels
endothelium and it  has good antiaggregation effects.  The oxygen’s pharmacokinetic and
neo-angiogenesis effects and its effect on oxygen-dependent reactions inside the mitochon‐
dria’s  and  homeopathy  effect  on  the  other  organs  are  the  reasons  to  use  HBO  in  the
treatment of HF. Nuclear imaging by SPECT imaging in the evaluation between ischemic
and non-ischemic HF we performed, and followed with quantification per segments before
and after therapy in the evaluation positive therapeutic effect. We also performed RNV like
gold standard in the evaluation global and regional LVEF before and after the therapy. In
the  pilot  study  with  18  patients,  we  had  recovery  perfusion  in  all  patients  with  non-
ischemic HF.  Before therapy we finding with RNV average measured LVEF was 23.4%.
After treatment LVEF measured average 34, 3%. The results was increase by 10, 9% (from
5% to 20% measured individually).
Conclusion of this pilot study was that diagnostic information finding by nuclear cardiology
(perfusion and function) suggested significantly positive therapy effects HBO and Erythro‐
poietin in the therapy of heart failure ischemic and non-ischemic origin.
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Case report 1. Patient female with multi vessel disease by coronarography
 
SPECT with DipyEX (dipyridamole = concomitant low level exercise 50W) performed and evaluated before and after
HBO + EPO therapy
 
 
quantification of perfusion by Stierner 
- segments quantification 10/10/2009 
 
quantification of perfusion by Stierner 
- segments quantification 07.13.2009 
 
Radonuclide ventriculography for evaluating global ejection fraction Performed before and after HBO = EPO therapy
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 radionuclide ventriculography (RNV) 
performed 10.12.2009 after therapy 
 
radionuclide ventriculography (RNV) 
performed 07.17. 2009 before therapy 
radionuclide ventriculography (RNV) 
regional ejection fraction 
performed 07.17. 2009 before therapy 
 
radionuclide ventriculography (RNV) 
regional ejection fraction 
performed 10.12.2009 after therapy 
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Case report 2. Male with non-ischemic heart failure
SPECT scan performed before HBO = EPO therapy
 
SPECT MPI performed 13.01.2011 
Scan pattern - dilatative myocardiopathy 
non-ischemic type 
Radionuclide venticulography performed before and after HBO = EPO therapy when we seen
the greatest increase of LVEF with improve wall motion and regional kinetics
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 RNV  with global and regional ejection fraction performed 01.17. 2011 – before therapy 
RNV  with global and regional ejection fraction performed 03.23. 2011 – after therapy 
Summary
The field of cardiovascular imaging is changing. In one hand, myocardial perfusion imaging
is a well/established clinical technique for the diagnostic and prognostic workup of coronary
artery disease. It has been the mainstay of nuclear cardiology for decades. On the other hand,
several alternative imaging methodologies for noninvasive functional assessment of ischemic
heart disease have emerged, and noninvasive coronary angiography is becoming a clinical
reality. Nuclear imaging technology has progressed significantly toward higher sensitivity
and resolution, and novel, highly specific radiotracers have been introduced. These develop‐
ments are indicator of steady evolution of nuclear cardiology beyond the assessment of
myocardial perfusion and toward characterization of biologic events on the tissue level. It is
Nuclear Cardiology — In the Era of the Interventional Cardiology
http://dx.doi.org/10.5772/55484
223
hoped that radiotracers techniques, with their unique translational potential and their superior
detection sensitivity, will take a leading role in personalized cardiovascular medicine, in which
therapeutic and/or preventive strategies are based on individual disease biology. The value of
more specific imaging targets, which are increasingly entering clinical practice. This includes
imaging of heart failure, absolute quantification of myocardial blood flow, imaging of
myocardial metabolism, and imaging of the cardiac autonomic nervous system.
The goal of this chapter is to provide the reader with a comprehensive overview of the most
recent development in nuclear cardiology, in the era of interventional cardiology. It is hoped
that the reader, after going through this article, will share the enthusiasm of the author for this
discipline, which holds the potential to be a key component in the new paradigm of early
detection coronary artery disease for indication for interventional cardiology, as well as
assessment new therapeutic effect (HBO + EPO) of heart failure.
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